Sun Pharmaceutical Industries Ltd. saw its shares drop over 4% in morning trade on Friday after the company announced its Q4 results. As of 9:15 AM, the shares were trading 3.53% lower at Rs 1,658.00.
The pharma major posted a revenue of ₹12,958.8 crore, up 8.1% from ₹11,982.9 crore in Q4FY24. However, this fell short of CNBC-TV18’s poll estimate of ₹13,039.2 crore, which expected a 9% year-on-year rise.
Net profit disappointed the Street, coming in at ₹2,153.9 crore — a sharp 19% decline from ₹2,658.7 crore in the year-ago quarter. Analysts had projected a 10% growth, estimating profit at ₹2,934 crore.
On a positive note, EBITDA rose 22.4% to ₹3,715.9 crore, beating the Street’s forecast of ₹3,618 crore, which had anticipated a 19% increase. The company’s EBITDA margin also expanded to 28.7% from 25.3% in Q4FY24, signaling improved operational efficiency.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash